MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40123-025-01252-6

Медицинская библиотека · Ophthalmology and therapy · 2025

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.

Tillmann Anne, Stillenmunkes Richard, Garweg Justus G, Cattaneo Jennifer, Bartolomeo Nicolò, Grimaldi Gabriela, Spitznagel Tahm, De Oliveira Figueiredo Eva C, Ambresin Aude, Menghini Moreno, Somfai Gábor M, Zweifel Sandrine, Fröhlich Jacqueline, Artemiev Dmitri, Ebneter Andreas, Hatz Katja, Weinberger Andreas, Pfister Isabel B, Schild Christin, Eandi Chiara, Munk Marion R, Swiss Retina Research Network

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

This study evaluates the efficacy and safety of faricimab in a real-world cohort of treatment-naïve patients with neovascular age-related macular degeneration (nAMD). Data were retrospectively collected from 130 eyes of 118 patients across 11 centers of the Swiss Retina Research Network, all treated with faricimab using a treat-and-extend regimen and followed for 12 months between May 2022 and October 2024.

METHODS

Demographic data, visual and anatomical outcomes, treatment intervals, and adverse events were extracted from the electronic medical records over a 12-month follow-up period. Main outcomes included change in best corrected visual acuity (BCVA), central retinal thickness (CRT), presence of intra- and subretinal fluid, retinal pigment epithelial detachment (PED), injection intervals, and safety. Data are presented as mean ± standard deviation.

RESULTS

Twelve months after the initiation of faricimab therapy, mean BCVA improved from 64.6 ± 14.1 to 69.2 ± 20.3 ETDRS (Early Treatment of Diabetic Retinopathy Study) letters (p < 0.001), while mean CRT decreased from 386.3 ± 172.3 to 246.6 ± 90.4 μm (p < 0.001). An early anatomical response to faricimab was observed in 34.6% of eyes achieving complete retinal fluid resolution after the first injection and in 55.6% after 12 months. The mean treatment interval was extended to 10.5 ± 4.3 weeks, with 26.2% of eyes achieving intervals of 8-11 weeks and 39.2% achieving intervals of ≥ 12 weeks after 12 months. Intraocular inflammation occurred in 0.77% of eyes (n = 1, anterior uveitis); serious adverse events were not reported.

CONCLUSION

Faricimab demonstrates favorable anatomical and functional outcomes with extended treatment intervals in a majority of patients with treatment-naïve nAMD, offering the potential of reduced treatment burden and the absence of retinal fluid in more than half of the subjects during the first year, while maintaining safety in a real-world setting.

Для цитирования: Tillmann Anne, Stillenmunkes Richard, Garweg Justus G, Cattaneo Jennifer, Bartolomeo Nicolò, Grimaldi Gabriela, Spitznagel Tahm, De Oliveira Figueiredo Eva C, Ambresin Aude, Menghini Moreno, Somfai Gábor M, Zweifel Sandrine, Fröhlich Jacqueline, Artemiev Dmitri, Ebneter Andreas, Hatz Katja, Weinberger Andreas, Pfister Isabel B, Schild Christin, Eandi Chiara, Munk Marion R, Swiss Retina Research Network. One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report.. Ophthalmology and therapy. 2025. DOI: 10.1007/s40123-025-01252-6.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.